ZIOPHARM Reports First-Quarter 2015 Financial Results and Recent Activities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Ziopharm Oncology (ZIOP) Posts Q1 Loss of 69c/Share
May 7, 2015 4:42 PM EDTZiopharm Oncology (NASDAQ: ZIOP) reported Q1 EPS of ($0.69), $0.56 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $272 thousand versus the consensus estimate of $130 thousand.
Recent and Upcoming Corporate Highlights
In January, ZIOPHARM and its partner, Intrexon Corporation, entered into an exclusive license agreement with The University of Texas MD Anderson Cancer Center for programs and associated technologies related to the development of non-viral adoptive cellular therapies, including CAR T, TCR and associated cell-based therapies. When combined with Intrexon's technology suite and ZIOPHARM's further clinical validation of the RheoSwitch... More
